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(dacarbazine and vemurafenib) in Canada from a societal perspective. Methods: 
A partitioned survival analysis model with 3 health states (pre-progression, 
post-progression, dead) estimated direct and indirect costs and quality-adjusted 
life-years (QALYs) for patients with BRAF V600+ advanced or metastatic melanoma 
receiving 1L treatment with trametinib, dacarbazine, or vemurafenib. Clinical 
inputs for trametinib and dacarbazine were from the METRIC trial (in the 1L 
chemotherapy group, 87%, 6% and 6% of patients received dacarbazine, paclitaxel, 
and no drug, respectively). Clinical inputs for vemurafenib were from an indirect 
treatment comparison of data from the METRIC and BRIM-3 studies. Resource 
utilization data were derived from physician survey results, drug costs from the 
manufacturers’ price and Quebéc medications lists, and other costs from pub-
lished sources. Consistent with a prior evaluation of vemurafenib, a 5-year time 
horizon was used. Costs and QALYs were discounted at 5% annually. Results: 
QALYs gained with trametinib were 0.4160 vs. dacarbazine and 0.1241 vs. vemu-
rafenib. Compared with dacarbazine, incremental costs for trametinib were 
$61,226, resulting in a cost of $147,177 per QALY gained. Compared to vemurafenib, 
trametinib yielded a cost savings of $26,553 and was therefore dominant (less 
costly, more effective). Probabilistic sensitivity analyses showed a 14% and 98% 
probability of trametinib being cost effective vs. dacarbazine and vemurafenib, 
respectively, based on a $100,000/QALY threshold. ConClusions: In patients with 
BRAF V600+ advanced or metastatic melanoma, 1L treatment with trametinib may 
not be cost-effective vs. dacarbazine but may be cost-effective vs. vemurafenib. 
There is uncertainty in the vemurafenib comparison given the lack of head-to-
head data.
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Cost-EffECtivENEss of ArsENiC trioxidE + All-trANs rEtiNoiC 
ACid ComPArEd with All-trANs rEtiNoiC ACid + idArubiCiN iN thE 
trEAtmENt of NEwly diAgNosEd ACutE PromyEloCytiC lymPhomA 
lEuKEmiA iN CANAdA
Lachaine J.1, Mathurin K.1, Barakat S.2
1University of Montreal, Montreal, QC, Canada, 2Lundbeck Canada, Montreal, QC, Canada
objeCtives: Acute promyelocytic leukemia (APL) constitutes a distinct and rare 
variant of acute myeloid leukemia and is characterized by a high early mortality 
rate. Although current treatments (all-trans retinoic acid (ATRA), anthracyclines, 
including idarubicin, IDA, and conventional chemotherapy) are associated with high 
remission rates, cytotoxic effects of chemotherapy treatment are still a concern in 
the management of newly diagnosed APL. The objective of this study was to assess, 
from a Canadian perspective, the economic impact of arsenic trioxide (ATO) +ATRA 
compared to ATRA+IDA in the treatment of newly diagnosed APL. Methods: The 
cost-effectiveness of ATO+ATRA compared to ATRA+IDA in the treatment of newly 
diagnosed APL was assessed over a lifetime horizon using a time-dependent Markov 
model. The model comprises four health states: complete remission, treatment 
failure or relapse, post-failure, and death. The length of each Markov cycle was 
one month for the first 48 months and one year thereafter. All patients started in 
the complete remission state and could move to other health states thereafter, 
according to the respective efficacy of each treatment. The model also takes into 
account the incidence of adverse events reported in a head-to-head trial. Utility or 
disutility values associated with each health state and adverse events were used 
to estimate the number of QALYs associated with each treatment. Analyses were 
conducted from both a Canadian Ministry of Health (MoH) and a societal perspec-
tive. Results: Compared with ATRA+IDA, ATRA+ATO is associated with ICERs of 
$84,092/QALY and $80,946/QALY, from a MoH and societal perspective respectively. 
Results of the probabilistic sensitivity analysis indicated that the ICER remains 
below $100,000 in 99.82% and 99.98% of the simulations from a MoH and a societal 
perspective respectively. ConClusions: This economic evaluation suggests that 
ATO+ATRA can be considered a cost-effective option for the first-line treatment of 
newly diagnosed APL patients.
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PArtiAlly CovErEd sElf-ExPANdAblE mEtAl stENts ArE morE Cost-
EffECtivE whEN ComPArEd to PlAstiC stENts for PAtiENts with distAl 
mAligNANt biliAry obstruCtioN
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objeCtives: Partially covered self expandable metal stents (SEMS) and polyethyl-
ene stents (PES) are commonly used for distal malignant biliary obstruction. SEMS 
are more efficacious yet expensive than PES. The cost-effectiveness of both stents 
using contemporary estimates was assessed. Methods: A decision tree compar-
ing initial palliative placement of PES versus SEMS was constructed for patients 
with distal malignant biliary obstruction requiring palliation with one-year fol-
low-up. Patients underwent an endoscopic retrograde cholangiopancreatography 
(ERCP) to insert the initial stent, and were followed by a gastroenterologist every 
3 months. If the insertion failed, a percutaneous transhepatic cholangiogram was 
performed. If stent occlusion occurred, a PES was then inserted at repeat ERCP, either 
in an outpatient setting, or after admission to hospital if cholangitis was present. 
Effectiveness was expressed as the likelihood of no occlusion. Costs were measured 
in US dollars. Probabilities were issued from a recent published randomized clini-
cal trial. Results: A PES-first strategy was dominated by a SEMS-first approach. 
The average cost was $6,541 USD for initial SEMS and $19,054 USD for initial PES, 
associated with respective effectiveness probabilities of 65.6% and 13.9% (likeli-
hood of experiencing no occlusion over 12 months). Sensitivity analyses confirmed 
the robustness of these results. They are however limited by the randomized trial 
where the probabilities were derived from, with regards to sample size and gener-
alizability. ConClusions: At the time of initial endoscopic drainage for patients 
with malignant biliary obstruction undergoing palliative stenting, an initial SEMS 
approach is both more effective and less costly than a PES-first strategy, regardless 
of anticipated survival or cost setting
conducted to test the robustness of the model. Results: The base-case ACER 
was $114k/QALY for abiraterone, $85k/QALY for sipuleucel-T, and $31k/QALY for 
prednisone. The base-case ICER was $389k/QALY for abiraterone, $547k/QALY for 
sipuleucel-T. Prednisone dominates both abiraterone and sipuleucel-T in terms 
of NMB at WTP thresholds of < $400k. At WTP thresholds of < $275k, sipuleucel-
T dominates abiraterone. One-way sensitivity analyses revealed that the model 
was most sensitive to overall survival and utility inputs. Probabilistic sensitivity 
analyses showed abiraterone to be cost-effective > 50% of the time at a WTP 
of > $400k, while sipuleucel-T was cost-effective > 50% of the time at a WTP of 
> $270k. ConClusions: Neither abiraterone nor sipuleucel-T was found to be 
cost-effective compared to prednisone in the treatment of asymptomatic, pre-
docetaxel mCRPC.
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A NovEl ColorECtAl CANCEr modEl with sEssilE sErrAtEd AdENomA 
PAthwAy to EvAluAtE thE Cost-EffECtivENEss of vArious sCrEENiNg 
strAtEgiEs
Zheng P., Dinh T.
Archimedes Inc., San Francisco, CA, USA
objeCtives: Sessile serrated adenoma (SSA) was recently recognized as a sepa-
rate pathway that accounts for 10-35% of colorectal cancers (CRCs). Current CRC 
screening tests exhibit inferior performance detecting SSAs as compared to other 
lesion types. Most existing CRC models do not include the SSA pathway; thus, the 
cost effectiveness of CRC screening in the face of inferior SSA detection remains 
uncertain. We developed a novel CRC model that incorporates the SSA pathway 
to evaluate the cost-effectiveness of various screening strategies. Methods: We 
modeled CRC progression in a simulated cohort of 100,000 individuals from age 
50 to 75 that were representative of the general US population. We investigated 
several CRC screening strategies within this cohort: colonoscopy every ten years 
(Q10 COLO); fecal immunochemical testing (FIT) every one, two, or three years (Q1 
FIT, Q2 FIT or Q3 FIT); and a hybrid strategy of colonoscopy every ten years with 
FIT one, two, or three years after negative colonoscopy (COLO/FIT 1, COLO/FIT 2, 
COLO/FIT 3). The primary outcomes were cancer incidence, medical cost, quality-
adjusted life-year (QALY), and incremental cost-effectiveness ratio (ICER) per QALY. 
We assumed full screening compliance. All economic outcomes were discounted 
at 3% per year. Results: All screening strategies were cost saving compared to 
no screening. The COLO/FIT 2 hybrid strategy reduced cancer incidence the most 
(59% compared to no screening) and gained the most QALYs compared to no 
screening (15,200 QALYs for every 100,000 people). Compared with the standard 
Q10 COLO strategy, COLO/FIT hybrid strategies produced ICERs of approximately 
$3,300 per QALY. ConClusions: Despite the comparatively poor performance 
of colonoscopy and FIT in detecting SSAs, our simulation results suggested that 
CRC screening would save costs and increase QALYs. Hybrid screening strate-
gies with colonoscopy and FIT were cost-effective compared to screening with 
colonoscopy alone.
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Cost-EffECtivENEss ANAlysis of bENdAmustiNE-rituximAb trEAtmENt 
ComPArEd with fludArAbiNE-rituximAb trEAtmENt, iN PAtiENts with 
iNdolENt NoN-hodgKiN’s lymPhomA iN PANAmá
Desanvicente-Celis Z.1, Obando C.A.1, Rodriguez E.1, Gonzalez L.2, Muschett D.1
1Janssen, Panama City, Panama, 2Janssen, Raritan, NJ, USA
objeCtives: To assess the cost-effectiveness of Bendamustine-Rituximab (BR) 
compared with Fludarabine-Rituximab (FR) treatment, in patients with Indolent 
Non-Hodgkin’s Lymphoma (INHL) that have progressed during or within six 
months of treatment with Rituximab or a Rituximab-containing Regimen in 
Panamá. Methods: A three-health state cohort simulation Markov Model (progres-
sion-free, progressive disease, and death) was developed, based on time-dependent 
progression-free survival and overall survival data. The time frame was lifetime 
(35 years). The perspective was that of the National Health System of Panamá. The 
health outcomes of interest were Quality Adjusted Life Years (QALYs), Life Years 
(LYs), and Progression-free Life Years (PFLYs). Resource consumption for health 
states was elicited with the support of Latin American hematologists. Utilities for 
health states and disutility for adverse reactions were taken from published stud-
ies. All costs and Incremental Cost Effectiveness Ratios (ICERs) are presented in 
United States Dollars. Costs and outcomes were discounted at 3%. One way and 
probabilistic sensitivity (PSA) analysis were performed. Results: BR resulted in 
4,641 QALYs/ 6,432 LYs/ and 3,564 PFLYs, per patient, respectively. FR resulted in 3,557 
QALYs/5,138 LYs and 2,047 PFLYs, per patient, respectively. Total costs were: 140.768 
for BR and 125.097 for FR. ICERs were: 14.468 per QALY gained, 12.114 per LY gained 
and 10.331 per PFLY gained. In all outcomes, results were sensitive to Hazard Ratio of 
overall survival. According to the PSA, with QALYs as outcome, BR had a probability 
of 39% of being cost effective when considering the threshold of 3 times the Gross 
Domestic Product per capita (GDPPC) of Panamá (28.602). ConClusions: BR can 
be considered cost-effective compared with FR in the study population (INHL) in 
Panamá, according to the classification suggested by the World Health Organization 
[cost effective between 1 and 3 GDPPC (9534-28602)].
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Cost EffECtivENEss of trAmEtiNib As first-liNE (1l) trEAtmENt for 
brAf v600 PositivE AdvANCEd or mEtAstAtiC mElANomA — A CANAdiAN 
soCiEtAl PErsPECtivE
Amdahl J1, Wang A.1, Thabane M.2, Amonkar M.3, Delea T.E.1
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2GlaxoSmithKline, Mississauga, ON, Canada, 
3GlaxoSmithKline, Collegeville, PA, USA
objeCtives: The METRIC trial demonstrated clinical benefits of trametinib vs. 
chemotherapy (dacarbazine or paclitaxel) in patients with BRAF V600+ advanced or 
metastatic melanoma overall, and in a subgroup receiving 1L treatment. We evalu-
ated the cost-effectiveness of trametinib as a 1L treatment vs. approved treatments 
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dominated vemurafenib. For sensitivity analysis, 95% of the variance was accounted 
for by health state utilities and cost of dabrafenib. ConClusions: Dabrafenib is the 
most cost-effective treatment for metastatic melanoma in patients with BRAFV600 
mutation given our assumptions. Given the similar QALYs and side effects profile of 
dabrafenib and vemurafenib, but higher drug cost of vemurafenib, a 25% price reduc-
tion for vemurafenib could bring this drug into the cost-effective range. A specific 
decrease of 63% in utility of progression on dabrafenib or a minimum decrease of 
28% for utility of stable disease on dabrafenib is needed to make vemurafenib the 
most cost-effective option.
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Cost-EffECtivENEss of AfAtiNib, ErlotiNib, ANd CisPlAtiN/PEmEtrExEd 
for first-liNE trEAtmENt of mEtAstAtiC Egfr-mutAtioN PositivE NoN-
smAll CEll luNg CANCEr
Ting J.1, Ho T.1, Xiang P.1, Abdel-Sattar M.1, Sugay A.1, Wilson L.S.2
1University of California: San Francisco, San Francisco, CA, USA, 2University of California San 
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objeCtives: To evaluate the cost-effectiveness of afatinib, erlotinib, and cis-
platin/pemetrexed chemotherapy, for first-line treatment of metastatic EGFR-
mutation positive non-small cell lung cancer (NSCLC). Methods: A Markov 
model simulated the lifetime progression of EGFR-mutation positive stage IIIB/
IV NSCLC patients, under each treatment option, from a US societal perspective. 
Probabilities, survival rates and health utilities were obtained from clinical trials 
(LUX-3, LUX-6, EURTAC and OPTIMAL) and published literature. Progression-free 
and overall survival in the erlotinib trial were adjusted up to account for differ-
ences in poorer ECOG performance status compared to the afatinib trial. Costs 
included those for drugs, progression, and side effects in 2013 USD. Expected 
QALYS were calculated. The impact of varying parameters on model outcomes 
was examined using probabilistic sensitivity analyses. Results: In the base-case 
model, treatment with afatinib was least expensive, with lifetime cost of $38,406, 
followed by cisplatin/pemetrexed ($40,714), and erlotinib ($41,344). Survival was 
highest with erlotinib (5.27 quality-adjusted life-months saved [QALMS]), followed 
by afatinib (4.02 QALMS), and cisplatin/pemetrexed (3.51 QALMS). Compared 
to erlotinib, afatinib had lower monthly drug costs ($5,648 versus $5,853), but 
higher overall side effects costs ($3,669 versus $1,690). Cisplatin/pemetrexed 
was dominated by afatinib. Erlotinib was cost-effective compared with afatinib 
(ICER= $28,210/QALYS). In a model without survival adjustments, afatinib com-
pared with erlotinib had an ICER over the WTP threshold (ICER= $542,745/QALYS), 
with erlotinib remaining the cost-effective option. Afatinib becomes more cost-
effective than erlotinib when its monthly drug cost decreased from $5,648 to below 
$3,802. ConClusions: Based on our analyses, we recommend erlotinib as the 
most cost-effective first-line treatment for EGFR-mutation positive NSCLC. Given 
the potentially similar relative efficacy between afatinib and erlotinib in the clini-
cal trials, cost-effectiveness analysis of afatinib versus erlotinib depends mostly 
on differences in drug and side-effects costs. Thus, afatinib may need to earn its 
share of the NSCLC market space with more competitive pricing.
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Cost-EffECtivENEss of ArsENiC trioxidE iN thE trEAtmENt of 
rElAPsEd/rEfrACtory ACutE PromyEloCytiC lymPhomA lEuKEmiA iN 
CANAdA
Lachaine J.1, Mathurin K.1, Barakat S.2
1University of Montreal, Montreal, QC, Canada, 2Lundbeck Canada, Montreal, QC, Canada
objeCtives: Acute promyelocytic leukemia (APL) constitutes a rare disease char-
acterized by a high mortality rate at early stage of treatment. Current first-line 
treatments consist of all-trans retinoic acid (ATRA), anthracyclines and conventional 
chemotherapy (CT). Although APL has currently a good prognosis, 20 to 30% of 
patients who achieved remission still relapse and are further resistant to the treat-
ment previously administrated. The objective of this study was to assess, from a 
Canadian perspective, the economic impact of arsenic trioxide (ATO) compared to 
ATRA+CT in the treatment of relapsed/refractory APL. Methods: The cost-effec-
tiveness of ATO compared to ATRA+CT in the treatment of relapsed/refractory APL 
was assessed over a lifetime horizon using a time-dependent Markov model. The 
model comprises five health states: induction, second remission, treatment failure 
or relapse, post-failure, and death. The length of each Markov cycle was one month 
for the first 24 months and one year thereafter. All patients started in the induction 
state and could move to other health states thereafter, according to the respective 
efficacy of each treatment. The model also takes into account the incidence of 
grade 3-4 adverse events reported in clinical trials. Utility or disutility values associ-
ated with each health state and adverse events were used to estimate the number 
of QALYs associated with each treatment. Analyses were conducted from both a 
Canadian Ministry of Health (MoH) and a societal perspective. Results: Compared 
with ATRA+CT, ATO was associated with incremental cost-effectiveness ratios of 
$18,380/QALY from a MoH perspective and $20,156/QALY from a societal perspec-
tive. Results of the probabilistic sensitivity analysis indicated that ATO remains a 
cost-effective strategy in 99.96% and 92.45% of the simulations, from a MoH and a 
societal perspective respectively. ConClusions: This economic evaluation sug-
gests that ATO is a cost-effective strategy compared to ATRA+CT in the treatment 
of relapsed/refractory APL in Canada.
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Cost-EffECtivENEss ANAlysis of iNNovAtioN iN hEmAtologiC 
mAligNANCiEs
Lin P.J.1, Winn A.2, Parsons S.K.1, Neumann P.J.1, Cohen J.T.1
1Tufts Medical Center, Boston, MA, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, 
NC, USA
objeCtives: To examine the costs of hematologic malignancies (HMs) in relation 
to survival gains among Medicare beneficiaries. Methods: Using the Surveillance, 
Epidemiology, and End Results (SEER)-Medicare datasets, we identified 99,721 
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A Cost EffECtivENEss ANAlysis of 4 ChEmothErAPy rEgimENs iN thE 
trEAtmENt of PlAtiNum sENsitivE rECurrENt EPithEliAl ovAriAN 
CArCiNomA
Burbano-Levy X.1, Schroeder E.D.2, Diaz J.P.2
1Zilonis Health, Boca Raton, FL, 2University of Miami, Miami, FL, USA
objeCtives: Compare the cost effectiveness of 4 chemotherapy treatments for 
platinum-sensitive recurrent epithelial ovarian carcinoma (EOC). Methods: A 
Markov model was constructed using a hypothetical cohort of 500 women (median 
age 60) to compare 4 NCCN recommended treatment-regimens for platinum sensi-
tive recurrent EOC: carboplatin/paclitaxel (C/P); carboplatin/gemcitabine (C/G), C/G 
with bevacizumab (C/G+B); and carboplatin/pegylated liposomal doxorubicin (C/
PLD). These treatments were chosen as they are each supported by phase III trials. 
An indirect treatment comparison methodology was used to obtain evidence of the 
difference in treatment effects of each regimen. Progression free survival (PFS) and 
overall survival (OS) data were used for survival comparisons. The time horizon was 
thirty years. Cost calculations were based on data from Medicare and published 
literature, and were based on median cycle number from each trial. Published values 
of health utilities were used for QALY calculations. Cost effectiveness ratios (CER) 
were calculated for each regimen, and expressed as 3 incremental cost effectiveness 
ratios (ICER): additional month PFS, month OS, and QALY. Reported rates of grade 3/4 
toxicities from each trial were added to the cost of each treatment. Cost, survival, 
and toxicity rate were varied over a range for sensitivity analysis. Results: C/G 
was a cost-effective regimen. The cost for treating 1 woman with 6 cycles of C/G 
ranged from $1,140 (no toxicity) to $7,030 (toxicities at the reported rate). Treatment 
with C/G produced a dominant ICER of $236,318/month-PFS. For each PFS-month 
gained over the next most cost-effective option, over $200,000 was saved. C/G was 
the dominant strategy for OS, (ICER= $72,213/month OS). When adjusted for health 
utility, C/G was the dominant strategy (ICER of $20,443/QALY). ConClusions: C/G 
was a cost-effective regimen, resulting in a dominant ICER for PFS, OS, and QALY. C/G 
resulted in a savings compared to the next most cost effective regimen.
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mobiliziNg Autologous hEmAtoPoiEtiC stEm CElls iN PAtiENts 
with myElomA: A ECoNomiC ComPArisoN of 4 CommoN mobilizAtioN 
strAtEgiEs
Tay J., Sheppard D., Bredeson C., Allan D., Coyle D.
University of Ottawa, Ottawa, ON, Canada
objeCtives: Autologous stem cell transplantation (ASCT) is an integral part in the 
management of Multiple Myeloma (MM), the 2nd most common blood cancer. The 
collection of self stem cells – mobilization is required for ASCT. The optimal approach 
to procurement of stem cells remains debatable, with multiple competing clinical, 
cost and transplant-centre factors. In order to rationalize a preferred collection 
strategy we sought to perform a cost-effectiveness analysis from a Funder’s perspec-
tive of 4 common mobilization strategies used in Canada: Cyclophosphamide/G-CSF 
(Strategy 1), G-CSF alone (Strategy 2), Upfront-use of Plerixafor (Strategy 3), and “Just-
in-time” use of Plerixafor (Strategy 4). Methods: Clinical data was derived from 
published systematic reviews, randomized trials and observational studies. Further, 
a local audit was performed to evaluate external validity of the published data. 
Costing data for SC collection and adverse events were derived locally, The Ottawa 
Hospital. All unsuccessful 1st attempts with each strategy were assumed to be fol-
lowed by plerixafor re-mobilization. Probabilistic sensitivity analysis around costs 
and collection probabilities were varied simultaneously across their plausible range 
of values using Monte Carlo simulations (MCS). Results: Successful collection 
rates were 94.5%, 88.3%, 97.8% and 98.0% respectively for Strategies 1-4, with rates 
of adverse event of febrile neutropenia of 25.7%, 0%, 0% and 0%. Costs/patient were 
estimated as $8649, $9098, $17,309 and $13,119 respectively. Strategy 1 dominated 
strategy 2 in terms of cost and successful mobilization. The incremental cost per 
successful mobilization was $137,000 for strategy 4 vs. 1 and $1.6 million for strat-
egy 4 vs. 3. MCS found that the probability that strategy 4 was most successful was 
70.6%. Strategy 1 was least costly in 72.6% of simulations. ConClusions: Within 
the constraints of our model, our analyses suggest that Cyclophosphamide/G-CSF 
is a reasonable stem cell mobilization strategy in patients with myeloma requiring 
an ASCT, balancing costs and successful mobilization.
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objeCtives: Melanoma is one of the fastest growing cancers worldwide and prog-
nosis is poor with metastases. In about 50% of melanoma patients the BRAFV600 
protein kinase mutation is present. Two BRAFV600 targeted therapies dabrafenib 
(Tafinlar®) and vemurafenib (Zelboraf®), have recently received U.S. approval to 
treat metastatic melanoma in BRAFV600patients. This study evaluated the cost-
effectiveness of BRAF inhibitors compared to traditional chemotherapy (dacar-
bazine). Methods: A Markov model was developed with three health states: stable 
disease, progression, and death and taking a lifetime societal perspective. Transition 
probabilities and clinical outcomes were derived from Phase III trials. Costs were 
in 2013 USD and derived from literature, national databases, and Medicare fees. 
Utilities for melanoma and other health states were obtained from studies con-
ducted on the general public. Deterministic and probabilistic sensitivity analyses 
were run to test the impact of uncertainties. Results: Cumulative cost of dacar-
bazine, dabrafenib and vemurafenib respectively were $15,282, $43,895, and $59,768. 
Monthly Drug costs were respectively $537, $7,570, and $10,807. Effectiveness of 
dacarbazine, vemurafenib and dabrafenib were 0.37, 0.5 and 0.52 LY, respectively and 
quality adjusted were 0.22, 0.35 and 0.39 QALY. The incremental cost-effectiveness 
ratio was $14,569 per QALY for dabrafenib compared to dacarbazine. Dabrafenib 
